Intismeran Autogene

Vaccine

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2030-06-25.

Also in development:Melanoma · Phase 3

Company guidance: data expected in 2026 (Moderna, 31 Jul 2026). “expectations regarding mRNA-4157 Phase 3 adjuvant melanoma data in 2026 and the potential of our oncology portfolio;” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Melanoma
Non-Small Cell Lung Cancer
Phase 2/3 (1)
Other / comorbidity
NCT06295809 · Merck Sharp & Dohme LLC
2024-04-18 – 2026-03-05 · Carcinoma, Squamous Cell, Skin Neoplasms
What this study did
Phase 2 (5)
Melanoma
NCT03897881 · ModernaTX, Inc.
2019-07-18 – 2032-11-21 · Melanoma
What this study did
NCT06961006 · Merck Sharp & Dohme LLC
2025-05-29 – 2031-09-05 · Malignant Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07221474 · Merck Sharp & Dohme LLC
2025-12-12 – 2031-05-06 · Squamous Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06307431 · Merck Sharp & Dohme LLC
2024-04-10 – 2032-06-08 · Renal Cell Carcinoma
What this study did
NCT06833073 · Merck Sharp & Dohme LLC
2025-03-11 – 2031-09-03 · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06305767 · Merck Sharp & Dohme LLC
2024-03-28 – 2031-10-20 · Bladder Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT03313778 · ModernaTX, Inc.
2017-08-14 – 2027-11-21 · Solid Tumors
What this study did

Competitive landscape

This drug's own stage for Melanoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Intismeran Autogene: this drugPhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Aldesleukin (Proleukin)ApprovedRecombinant Cytokine (il-2)Interleukin-2 receptor (IL-2R)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BinimetinibApprovedSmall moleculeMEK1/2Partial signal
NCT01763164: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71)
CobimetinibApprovedSmall moleculeMEK1/2Reliable signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Reliable signal
NCT01597908: Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7)
NCT01584648: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3)
EncorafenibApprovedSmall moleculeBRAF V600EPartial signalNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptorPartial signal
NCT01359956: Overall survival, interferon alfa-2b added vs not added to dacarbazine-based chemotherapy (2x2 factorial): HR 0.92 (95% CI 0.70 to 1.20), p=0.68 (Daponte et al., J Transl Med 2013). missed
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT00094653: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone (From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks)): Ipilimumab Plus gp100 9.95 months (95% CI 8.48 to 11.5) | gp100 6.44 months (95% CI 5.49 to 8.71)
Lifileucel (Amtagvi)ApprovedCell therapyTumor-infiltrating lymphocytes (polyclonal tumor antigens)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT01721746: CheckMate 037 coprimaries: objective response rate 31.7% (95% CI 23.5 to 40.8) in the first 120 nivolumab patients vs 10.6% (3.5 to 23.1) with investigator-choice chemotherapy at the interim analysis, reported without a between-group p-value; overall survival median 16 vs 14 months (HR 0.95, 95.54% CI 0.73 to 1.24), no difference (Weber, Lancet Oncol 2015; Larkin, JCO 2018). missed
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
RelatlimabApprovedMonoclonal antibodyLAG-3Reliable signal
NCT03470922: Progression Free Survival (PFS) (From randomization to date of first documented tumor progression or death (up to approximately 33 months)): Arm A: Relatlimab + Nivolumab 10.12 Months (95% CI 6.37 to 15.74) | Arm B: Nivolumab 4.63 Months (95% CI 3.38 to 5.62)
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
VemurafenibApprovedSmall moleculeBRAF (V600 mutant)Partial signalNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)ApprovedOncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CemiplimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FianlimabPhase 3Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)Phase 3Protein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signalNo reviewed efficacy summary in this indication
LNS8801Phase 2/3Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 2Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Intismeran Autogene to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 1/2Bladder CancerActive not recruiting
Est. primary completion 2027-04-23 · NCT06305767 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-11-21 · NCT03313778 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-01-08 · NCT06307431 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2028-07-22 · NCT06961006 · CT.gov ↗
What to watch
2029 (2)
July 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-02 · NCT07221474 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3MelanomaActive not recruiting
Est. primary completion 2029-10-26 · NCT05933577 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-06-25 · NCT06077760 · CT.gov ↗
What to watch
2031 (1)
September 2031 (1)
Phase 2Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in SituRecruiting
Est. primary completion 2031-09-03 · NCT06833073 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2032-11-21 · NCT03897881 · CT.gov ↗
What to watch
2033 (1)
May 2033 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2033-05-16 · NCT06623422 · CT.gov ↗
What to watch
2034 (1)
August 2034 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2034-08-22 · NCT07513376 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 August 2026Topline resultINTerpath-001 Phase 3 of intismeran autogene plus pembrolizumab meets RFS primary endpoint in resected melanoma
Merck & Co. and Moderna · Source ↗